Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia

被引：20

作者：

Annunziata, Mario ^{[1
]}

Bonifacio, Massimiliano ^{[2
]}

Breccia, Massimo ^{[3
]}

Castagnetti, Fausto ^{[4
]}

Gozzini, Antonella ^{[5
]}

Iurlo, Alessandra ^{[6
]}

Pregno, Patrizia ^{[7
]}

Stagno, Fabio ^{[8
]}

Specchia, Giorgina ^{[9
]}

机构：

[1] AORN Cardarelli Napoli, Hematol Div, Naples, Italy

[2] Univ Verona, Dept Med, Sect Hematol, Verona, Italy

[3] Sapienza Univ, Dept Translat & Precis Med, Rome, Italy

[4] Univ Bologna, S Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Dept Expt Diagnost & Specialty Med, Bologna, Italy

[5] AUO Careggi, Dept Cellular Therapy & Transfus Med, Florence, Italy

[6] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Hematol Div, Milan, Italy

[7] AOU Citta Salute & Sci Torino, Hematol Div, Oncol & Hematol Dept, Turin, Italy

[8] AOU Policlin V Emanuele, Div Hematol & Bone Marrow Transplant, Catania, Italy

[9] Univ Bari Aldo Moro, Dept Emergency & Organ Transplantat, Hematol Sect, Bari, Italy

来源：

FRONTIERS IN ONCOLOGY | 2020年 / 10卷

关键词：

chronic myeloid leukemia; deep molecular response; optimal strategies; treatment-free remission; tyrosine kinase inhibitors; TYROSINE KINASE INHIBITORS; IMATINIB DISCONTINUATION; FRONTLINE NILOTINIB; CLINICAL-PRACTICE; PEGINTERFERON ALPHA-2A; INTERFERON-ALPHA; RANDOMIZED-TRIAL; CML PATIENTS; DASATINIB; BCR-ABL1;

D O I：

10.3389/fonc.2020.00883

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The treatment of chronic myeloid leukemia (CML) has been radically changed by the approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity. CML is now managed as a chronic disease requiring long-term treatment and close molecular monitoring. It has been shown that in a substantial number of patients who have achieved a stable deep molecular response (DMR), TKI treatment can be safely discontinued without loss of response. Therefore, treatment-free remission (TFR), through the achievement of a DMR, is increasingly regarded as a feasible treatment goal in many CML patients. However, only nilotinib has approval in this setting and a number of controversial aspects remain regarding treatment choices and timings, predictive factors, patient communication, and optimal strategies to achieve successful TFR. This narrative review aims to provide a comprehensive overview on how to optimize the path to DMR and TFR in patients with CML, and discusses recent data and future directions.

引用

页数：12

共 98 条

[11] Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient- based survey on 1133 patients [J].

Breccia, Massimo ;

Efficace, Fabio ;

Sica, Simona ;

Abruzzese, Elisabetta ;

Cedrone, Michele ;

Turri, Diamante ;

Gobbi, Marco ;

Carella, Angelo Michele ;

Gozzini, Antonella ;

Usala, Emilio ;

Cavazzini, Francesco ;

Danise, Paolo ;

Tiribelli, Mario ;

Binotto, Gianni ;

Pregno, Patrizia ;

Bocchia, Monica ;

Gaidano, Gianluca ;

Crugnola, Monica ;

Bonifacio, Massimiliano ;

Avanzini, Paolo ;

Celesti, Francesca ;

Guella, Anna ;

Martino, Bruno ;

Annunziata, Mario ;

Luciano, Luigiana ;

Stagno, Fabio ;

Vallisa, Daniele ;

Pungolino, Esther ;

Iurlo, Alessandra ;

Rambaldi, Alessandro ;

Nardiello, Ida ;

Orlandi, Esther ;

Gambacorti-Passerini, Carlo ;

Alimena, Giuliana .

LEUKEMIA RESEARCH, 2015, 39 (10) :1055-1059

[12] Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia [J].

Burchert, Andreas ;

Mueller, Martin C. ;

Kostrewa, Philippe ;

Erben, Philipp ;

Bostel, Tilman ;

Liebler, Simone ;

Hehlmann, Ruediger ;

Neubauer, Andreas ;

Hochhaus, Andreas .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1429-1435

[13] Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients [J].

Carlos Hernandez-Boluda, Juan ;

Pereira, Arturo ;

Pastor-Galan, Irene ;

Alvarez-Larran, Alberto ;

Savchuk, Alisa ;

Manuel Puerta, Jose ;

Maria Sanchez-Pina, Jose ;

Collado, Rosa ;

Diaz-Gonzalez, Alvaro ;

Angona, Anna ;

Sagues, Miguel ;

Garcia-Gutierrez, Valentin ;

Boque, Concepcion ;

Osorio, Santiago ;

Vallansot, Rolando ;

Palomera, Luis ;

Mendizabal, Arantxa ;

Felipe Casado, Luis ;

Perez-Encinas, Manuel ;

Perez-Lopez, Raul ;

Ferrer-Marin, Francisca ;

Sanchez-Guijo, Fermin ;

Garcia, Carmen ;

de las Heras, Natalia ;

Luis Lopez-Lorenzo, Jose ;

Cervantes, Francisco ;

Luis Steegmann, Juan .

BLOOD CANCER JOURNAL, 2018, 8

[14] Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells [J].

Cayssials, Emilie ;

Jacomet, Florence ;

Piccirilli, Nathalie ;

Lefevre, Lucie ;

Roy, Lydia ;

Guilhot, Francois ;

Chomel, Jean-Claude ;

Leleu, Xavier ;

Gombert, Jean-Marc ;

Herbelin, Andre ;

Barbarin, Alice .

BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) :54-59

[15] Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia With Losing Major Molecular Response as a Definition for Molecular Relapse: A Systematic Review and Meta-Analysis [J].

Chen, Kang-kang ;

Du, Tai-feng ;

Xiong, Pei-sheng ;

Fan, Guan-hua ;

Yang, Wei .

FRONTIERS IN ONCOLOGY, 2019, 9

[16] De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial [J].

Clark, Richard E. ;

Polydoros, Fotios ;

Apperley, Jane F. ;

Milojkovic, Dragana ;

Rothwell, Katherine ;

Pocock, Christopher ;

Byrne, Jennifer ;

de lavallade, Hugues ;

Osborne, Wendy ;

Robinson, Lisa ;

O'Brien, Stephen G. ;

Read, Lucy ;

Foroni, Letizia ;

Copland, Mhairi .

LANCET HAEMATOLOGY, 2019, 6 (07) :E375-E383

[17] Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia [J].

Claudiani, Simone ;

Apperley, Jane F. ;

Deplano, Simona ;

Khorashad, Jamshid ;

Foroni, Letizia ;

Palanicawandar, Renuka ;

Perry, Richard ;

Milojkovic, Dragana .

AMERICAN JOURNAL OF HEMATOLOGY, 2016, 91 (11) :E480-E481

[18] Digital droplet PCR at the time of TKI discontinuation in chronic-phase chronic myeloid leukemia patients is predictive of treatment-free remission outcome [J].

Colafigli, Gioia ;

Scalzulli, Emilia ;

Porrazzo, Marika ;

Diverio, Daniela ;

Loglisci, Maria Giovanna ;

Latagliata, Roberto ;

Guarini, Anna ;

Foa, Robin ;

Breccia, Massimo .

HEMATOLOGICAL ONCOLOGY, 2019, 37 (05) :652-654

[19] Is There a Role for Dose Modification of TKI Therapy in CML? [J].

Copland, M. .

CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (04) :337-345

[20]

Cortes J, 2019, COMBINATION THERAPY

← 1 2 3 4 5 6 7 8 9 10 →